153 related articles for article (PubMed ID: 23326115)
1. Istaroxime: A rising star in acute heart failure.
Aditya S; Rattan A
J Pharmacol Pharmacother; 2012 Oct; 3(4):353-5. PubMed ID: 23326115
[TBL] [Abstract][Full Text] [Related]
2. Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure.
Gheorghiade M; Blair JE; Filippatos GS; Macarie C; Ruzyllo W; Korewicki J; Bubenek-Turconi SI; Ceracchi M; Bianchetti M; Carminati P; Kremastinos D; Valentini G; Sabbah HN;
J Am Coll Cardiol; 2008 Jun; 51(23):2276-85. PubMed ID: 18534276
[TBL] [Abstract][Full Text] [Related]
3. Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORIZON-HF) trial.
Shah SJ; Blair JE; Filippatos GS; Macarie C; Ruzyllo W; Korewicki J; Bubenek-Turconi SI; Ceracchi M; Bianchetti M; Carminati P; Kremastinos D; Grzybowski J; Valentini G; Sabbah HN; Gheorghiade M;
Am Heart J; 2009 Jun; 157(6):1035-41. PubMed ID: 19464414
[TBL] [Abstract][Full Text] [Related]
4. Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial.
Blair JE; Macarie C; Ruzyllo W; Bacchieri A; Valentini G; Bianchetti M; Pang PS; Harinstein ME; Sabbah HN; Filippatos GS; Gheorghiade M;
Am J Ther; 2008; 15(3):231-40. PubMed ID: 18496261
[TBL] [Abstract][Full Text] [Related]
5. Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure.
Sabbah HN; Imai M; Cowart D; Amato A; Carminati P; Gheorghiade M
Am J Cardiol; 2007 Jan; 99(2A):41A-46A. PubMed ID: 17239704
[TBL] [Abstract][Full Text] [Related]
6. Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes?
Khan H; Metra M; Blair JE; Vogel M; Harinstein ME; Filippatos GS; Sabbah HN; Porchet H; Valentini G; Gheorghiade M
Heart Fail Rev; 2009 Dec; 14(4):277-87. PubMed ID: 19238540
[TBL] [Abstract][Full Text] [Related]
7. Istaroxime, a stimulator of sarcoplasmic reticulum calcium adenosine triphosphatase isoform 2a activity, as a novel therapeutic approach to heart failure.
Micheletti R; Palazzo F; Barassi P; Giacalone G; Ferrandi M; Schiavone A; Moro B; Parodi O; Ferrari P; Bianchi G
Am J Cardiol; 2007 Jan; 99(2A):24A-32A. PubMed ID: 17239701
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of the New Inotropic Agent Istaroxime in Acute Heart Failure.
Forzano I; Mone P; Mottola G; Kansakar U; Salemme L; De Luca A; Tesorio T; Varzideh F; Santulli G
J Clin Med; 2022 Dec; 11(24):. PubMed ID: 36556120
[TBL] [Abstract][Full Text] [Related]
9. Istaroxime: a new luso-inotropic agent for heart failure.
Mattera GG; Lo Giudice P; Loi FM; Vanoli E; Gagnol JP; Borsini F; Carminati P
Am J Cardiol; 2007 Jan; 99(2A):33A-40A. PubMed ID: 17239702
[TBL] [Abstract][Full Text] [Related]
10. Istaroxime: A Novel Therapeutic Agent for Acute Heart Failure.
Newbury D; Frishman W
Cardiol Rev; 2023 Oct; ():. PubMed ID: 37811998
[TBL] [Abstract][Full Text] [Related]
11. Istaroxime, a potential anticancer drug in prostate cancer, exerts beneficial functional effects in healthy and diseased human myocardium.
Wallner M; Khafaga M; Kolesnik E; Vafiadis A; Schwantzer G; Eaton DM; Curcic P; Köstenberger M; Knez I; Rainer PP; Pichler M; Pieske B; Lewinski DV
Oncotarget; 2017 Jul; 8(30):49264-49274. PubMed ID: 28514771
[TBL] [Abstract][Full Text] [Related]
12. Chronic istaroxime improves cardiac function and heart rate variability in cardiomyopathic hamsters.
Lo Giudice P; Mattera GG; Gagnol JP; Borsini F
Cardiovasc Drugs Ther; 2011 Apr; 25(2):133-8. PubMed ID: 21287411
[TBL] [Abstract][Full Text] [Related]
13. Treatment with 24 hour istaroxime infusion in patients hospitalised for acute heart failure: a randomised, placebo-controlled trial.
Carubelli V; Zhang Y; Metra M; Lombardi C; Felker GM; Filippatos G; O'Connor CM; Teerlink JR; Simmons P; Segal R; Malfatto G; La Rovere MT; Li D; Han X; Yuan Z; Yao Y; Li B; Lau LF; Bianchi G; Zhang J;
Eur J Heart Fail; 2020 Sep; 22(9):1684-1693. PubMed ID: 31975496
[TBL] [Abstract][Full Text] [Related]
14. A phase 1-2 dose-escalating study evaluating the safety and tolerability of istaroxime and specific effects on electrocardiographic and hemodynamic parameters in patients with chronic heart failure with reduced systolic function.
Ghali JK; Smith WB; Torre-Amione G; Haynos W; Rayburn BK; Amato A; Zhang D; Cowart D; Valentini G; Carminati P; Gheorghiade M
Am J Cardiol; 2007 Jan; 99(2A):47A-56A. PubMed ID: 17239705
[TBL] [Abstract][Full Text] [Related]
15. Combining SERCA2a activation and Na-K ATPase inhibition: a promising new approach to managing acute heart failure syndromes with low cardiac output.
Gheorghiade M; Ambrosy AP; Ferrandi M; Ferrari P
Discov Med; 2011 Aug; 12(63):141-51. PubMed ID: 21878191
[TBL] [Abstract][Full Text] [Related]
16. Modulation of sarcoplasmic reticulum function by PST2744 [istaroxime; (E,Z)-3-((2-aminoethoxy)imino) androstane-6,17-dione hydrochloride)] in a pressure-overload heart failure model.
Rocchetti M; Alemanni M; Mostacciuolo G; Barassi P; Altomare C; Chisci R; Micheletti R; Ferrari P; Zaza A
J Pharmacol Exp Ther; 2008 Sep; 326(3):957-65. PubMed ID: 18539651
[TBL] [Abstract][Full Text] [Related]
17. Istaroxime, a positive inotropic agent devoid of proarrhythmic properties in sensitive chronic atrioventricular block dogs.
Bossu A; Kostense A; Beekman HDM; Houtman MJC; van der Heyden MAG; Vos MA
Pharmacol Res; 2018 Jul; 133():132-140. PubMed ID: 29753687
[TBL] [Abstract][Full Text] [Related]
18. Altered sarco(endo)plasmic reticulum calcium adenosine triphosphatase 2a content: Targets for heart failure therapy.
Liu G; Li SQ; Hu PP; Tong XY
Diab Vasc Dis Res; 2018 Jul; 15(4):322-335. PubMed ID: 29762054
[TBL] [Abstract][Full Text] [Related]
19. Increased sarcoplasmic/endoplasmic reticulum calcium ATPase 2a activity underlies the mechanism of the positive inotropic effect of ivabradine.
Xie M; Huang HL; Zhang WH; Gao L; Wang YW; Zhu XJ; Li W; Chen KS; Boutjdir M; Chen L
Exp Physiol; 2020 Mar; 105(3):477-488. PubMed ID: 31912915
[TBL] [Abstract][Full Text] [Related]
20. Istaroxime, a novel luso-inotropic agent for the treatment of acute heart failure.
Wehrens XH
Curr Opin Investig Drugs; 2007 Sep; 8(9):769-77. PubMed ID: 17729189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
